MORAb 066

Drug Profile

MORAb 066

Alternative Names: Anticancer monoclonal antibody (MORAb-066) - Janssen Biotech/Morphotek; MORAb-006

Latest Information Update: 10 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centocor Ortho Biotech
  • Developer Morphotek; Sarah Cannon Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Thromboplastin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 03 Aug 2016 Phase-I development is ongoing for Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer in USA (NCT01761240; Eisai pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Colorectal-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top